Sandoz Group Navigates Challenges with Strong Q1 Performance, Reaffirms 2025 Guidance

Isaac LaneWednesday, Apr 30, 2025 1:26 am ET
16min read

Sandoz Group, the generics and biosimilars division of

, reported Q1 2025 net sales of $2.48 billion, up 3% in constant currencies, confirming its full-year guidance of mid-single-digit sales growth and a core EBITDA margin of around 21%. Despite headwinds like price erosion and regulatory complexities, Sandoz’s focus on high-margin biosimilars and operational efficiency continues to drive resilience.

A Resilient Start to 2025

The Q1 results reflect Sandoz’s strategic shift toward biosimilars, which now account for 27% of sales ($671 million), up from 25% a year earlier. Biosimilars grew 11% in constant currencies, driven by launches like Hyrimoz (adalimumab) in Europe and Omnitrope (somatropin) in international markets. Generics, representing 73% of sales, grew modestly (+2% in cc), buoyed by the North American launch of paclitaxel and European market penetration.

Regional Dynamics: Europe Shines, North America Struggles

  • Europe: Sales rose 7% in cc, fueled by biosimilars and generics. Hyrimoz and Pyzchiva (natalizumab) contributed significantly.
  • North America: Sales grew just 1% in cc, hampered by the withdrawal of Cimerli (etelcalcetide). Excluding Cimerli, biosimilar sales grew 3%, while generics benefited from the paclitaxel launch.
  • International Markets: Sales fell 2% in cc overall, but rose 2% when excluding the divested China business. Omnitrope and other biosimilars offset weakness in some regions.

Drivers of Growth and Profitability

  1. Biosimilar Pipeline: Sandoz plans four major launches in 2025:
  2. Wyost/Jubbonti (denosumab) in Europe and the U.S.
  3. Tyruko (natalizumab) in the U.S.
  4. Afqlir (aflibercept) in Europe.
    These launches aim to push biosimilars to 30% of sales by 2028, boosting margins as they command higher prices than generics.

  5. Margin Expansion: The 21% EBITDA target hinges on:

  6. A sales mix shift toward biosimilars.
  7. Cost efficiencies from simplifying its supply chain and reducing external suppliers.
  8. Volume growth (+6% contribution to Q1 sales) offsetting price erosion (-3%).

  9. Tariff Mitigation: The U.S. imposed a 20% tariff on Chinese imports in March 2025, but Sandoz’s reliance on European and U.S. manufacturing (15 sites, 11 in Europe) limits exposure. U.S. sales account for less than 20% of total revenue.

Challenges and Risks

  • Price Erosion: While normalized to low to mid-single digits in 2025, continued pressure in generics remains a drag.
  • Regulatory Hurdles: Sandoz paused a Phase III trial for a pembrolizumab biosimilar, citing regulatory alignment efforts. It also sued Amgen for allegedly stifling competition for its Enbrel biosimilar Erelzi.
  • Divestments: The China business divestment in 2024 continues to affect international sales comparisons.

Long-Term Outlook: Biosimilars as the Engine

Sandoz has now posted 14 consecutive quarters of top-line growth, a streak underpinned by its biosimilar strategy. By 2028, it aims for mid-single-digit annual sales growth, with biosimilars contributing ≥30% of sales. Management emphasized that this trajectory is achievable through disciplined execution, regulatory advocacy, and cost controls.

Conclusion: A Steady Hand in a Volatile Sector

Sandoz’s Q1 performance reaffirms its ability to navigate a challenging environment. With biosimilars driving high-margin growth and a diversified manufacturing footprint mitigating tariffs, the company is well-positioned to meet its 2025 targets. Key metrics to watch include:
- Biosimilar sales growth: A 10–15% expansion in 2025 would validate its pipeline strength.
- Margin stability: A 21% EBITDA margin in 2025 would reflect successful cost-cutting and mix shifts.
- Regulatory wins: Success in litigation against Amgen could unlock untapped markets.

While risks like generic competition and macroeconomic uncertainty linger, Sandoz’s track record and strategic focus suggest it will remain a consistent performer in the generics and biosimilars space. For investors, this is a story of steady growth in a sector where affordability and innovation are increasingly prized.

Data sources: Sandoz Q1 2025 earnings release, prior quarterly performance reports.

Comments



Add a public comment...
No comments

No comments yet

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.